Association between rs823128 polymorphism and the risk of Parkinson's disease: A meta-analysis. (5th February 2018)

• Record Type: Journal Article
• Authors: Cai, Min; Liu, Zongchao; Li, Wenjian; Wang, Ying; xie, anmu
• Is Part Of: Neuroscience letters. Volume 665(2018)
• Page Start: 110
• Page End: 116
• Publication Date: 2018-02-05
• Subjects: Parkinson's disease -- PARK16 -- Polymorphism -- Meta-analysis; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2017.11.057
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: We performed a meta-analysis to assess the rs823128 polymorphism of PARK16 in PD. The rs823128 polymorphism in PARK16 could be a potential protective factor for PD in overall populations. The subgroup analysis showed rs823128 was a decreased risk factor for PD in Asian and Chilean populations. Abstract: Numerous published case-control studies have investigated a role of PARK16 gene in susceptibility to Parkinson's disease (PD), but the results remain conflicting and under-powered. Herein, we performed this meta-analysis to evaluate the possible association between the polymorphism of the PARK16 rs8231128 (A/G) and PD.A comprehensive search of six databases was conducted to identify all case-control studies involving PARK16rs823128variants and PD risk up to August 2017. The strict inclusion and exclusion criteria were applied. A total of 9 studies including 15 case-control studies with 7277 PD cases and 6188 controls were included in the meta-analysis. And STATA 12.0 statistics software was used to calculate available data from each study. The crude odds ratios (OR) and 95% confidence interval (CI) were calculated to assess the genetic association between PARK16 rs823128 polymorphism and the risk of PD. In the combined analysis, results showed a significant association between rs823128 and PD in allelic model(G vs. A: OR = 0.886, 95% CI = 0.811–0.969, P = 0.008), dominant model (GG+ AG vs. AA: OR = 0.886, 95% CI = 0.804–0.976, P = 0.014), and heterozygote model (AG vs. AA: OR = 0.897, 95% CI = 0.812-0.991, P = 0.032). Further, ethnicity based analysis showed a significant association in Asian and Chilean population, but not in Caucasian samples. Within its limitations, this meta-analysis demonstrated that the rs823128 variants(G allele, GA and GG genotype)in PARK16 might be a potential protective factor for PD. However, these associations vary in different ethnicities.